KADIMASTEM LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 478 ILa | 0.00% |
|
-1.10% | -19.39% |
| 28/03 | Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 28/02 | IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company | MT |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 2.49Cr 932.22Cr 207.74Cr |
|---|---|---|---|---|---|
| Net income 2022 | -2.2Cr -824.69Cr -183.78Cr | Net income 2023 | -1.2Cr -449.83Cr -100.24Cr | EV / Sales 2022 | - |
| Net Debt 2022 | 7L 28Cr 6.17Cr | Net Debt 2023 | 21.69L 81Cr 18Cr | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.76
x | P/E ratio 2023 |
-2.09
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 39.92% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -1.10% | ||
| Current month | -4.63% | ||
| 1 month | -1.01% | ||
| 3 months | -8.08% | ||
| 6 months | -19.12% | ||
| Current year | -19.39% |
1 week
430.00
515.00
1 month
430.00516.90
Current year
430.00725.00
1 year
430.00805.00
3 years
430.007 199.00
5 years
430.008 600.00
10 years
430.0094 210.00
| Managers | Title | Age | Since |
|---|---|---|---|
Asaf Shiloni
CEO | Chief Executive Officer | 54 | 01/21/01 |
Michel Revel
FOU | Founder | 85 | 06/08/06 |
Uri Ben-Or
DFI | Director of Finance/CFO | 52 | 14/22/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 73 | 17/20/17 | |
Tamar Galili
BRD | Director/Board Member | 51 | 03/22/03 |
Ronen Twito
CHM | Chairman | 49 | 23/20/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/24/19 | 478 | -1.10% | 3,887 |
| 16/24/16 | 483.3 | -1.39% | 507 |
Delayed Quote TEL AVIV STOCK EXCHANGE, June 20, 2024 at 07:54 pm IST
More quotes
Kadimastem Ltd is an Israel-based regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The Companyâs technology enables the differentiation of stem cells into insulin secreting beta cells, as well as a range of neural cells (including Oligodendrocytes, Astrocytes). The Company produces islet-like clusters that show glucose-stimulated insulin secretion. In addition, the Company is partnering with pharmaceutical companies interested to screen potential drug compounds (hit-lead, lead optimization) on its stem-cell derived cells, primarily oligodendrocytes and astrocytes.
| 1st Jan change | Capi. | |
|---|---|---|
| -19.39% | 53.77L | |
| +15.60% | 12TCr | |
| +20.39% | 11TCr | |
| +8.24% | 2.28TCr | |
| -20.23% | 2.07TCr | |
| -16.19% | 1.65TCr | |
| -13.77% | 1.64TCr | |
| -44.35% | 1.58TCr | |
| +2.35% | 1.35TCr | |
| +66.40% | 1.17TCr |
- Stock Market
- Equities
- KDST Stock
